Loading patent…
AssigneeAligos Therapeutics, Inc.
InventorsYannick Debing, Sandrine Vendeville, Megan Elizabeth Fitzgerald, Hannah Vanrusselt, Julian Alexander Symons
Estimating the term…
Provided herein are methods of treating a hepatitis B viral and/or a hepatitis D viral infection in a subject in need thereof. In some embodiments, the methods include administering an effective amount of a first agent selected from the group consisting of (i) an HBV surface antigen (HBsAg) reducing agent, or a pharmaceutically acceptable salt thereof, or and (ii) a capsid assembly modulator (CAM), or a pharmaceutically acceptable salt thereof, to the subject followed by administering an effective amount of a second agent selected from the group consisting of (i) a CAM, or a pharmaceutically acceptable salt thereof, and (ii) an HBV surface antigen (HBsAg) reducing agent, or a pharmaceutically acceptable salt thereof, to the subject, wherein when the first agent is an HBsAg reducing agent or a pharmaceutically acceptable salt thereof, the second agent is a CAM or a pharmaceutically acceptable salt thereof; and wherein when the first agent is a CAM or a pharmaceutically acceptable salt thereof, the second agent is an HBsAg reducing agent or a pharmaceutically acceptable salt thereof; and wherein the initial administration of the second agent is after a delay period following the initial administration of the first agent.
A method of treating hepatitis B viral (HBV) and/or hepatitis D viral (HDV) infection in a subject in need thereof comprising:
A method of maintaining low plasma HBsAg levels in a subject having an HBV and/or an HDV infection, comprising:
An improved method of treating a hepatitis B viral and/or a hepatitis D viral infection in a subject for whom therapy with a first agent selected from the group consisting of (i) an HBV surface antigen (HBsAg) reducing agent, or a pharmaceutically acceptable salt thereof, and (ii) a capsid assembly modulator (CAM), or a pharmaceutically acceptable salt thereof, has been initiated, the improved method comprising administering an effective amount of a second agent selected from the group consisting of (i) a CAM, or a pharmaceutically acceptable salt thereof, and (ii) an HBsAg reducing agent, or a pharmaceutically acceptable salt thereof, to the subject,
The improved method of claim 72, wherein the additional agent is selected from the group consisting of recombinant interferon alpha 2b, IFN-α, PEG-IFN-α-2a, lamivudine, telbivudine, adefovir dipivoxil, clevudine, entecavir, tenofovir alafenamide, and tenofovir disoproxil and an additional siRNA, or a pharmaceutically acceptable salt of any of the foregoing.
Dependencies are inferred from the claim text.